Peng Sihan, Tian Jing, Jin Luchang, Wang Hongyan, Xie Chunguang, Zheng Jie, Liu Linfeng, Cao Jun, Zhang Wen, Zhang Xiangeng
TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Front Pharmacol. 2023 Jul 26;14:1168863. doi: 10.3389/fphar.2023.1168863. eCollection 2023.
This study aims to evaluate the efficacy and safety of Danggui Niantong Decoction (DGNT) systematically on gout treating. This study was registered in PROSPERO, and the registration number was CRD42021271607. By the end of December, 2022, literature research was conducted among eight electronic databases. Main results of this study were blood uric acid (BUA) and Creactive protein (CRP). Secondary outcomes were erythrocyte sedimentation rate (ESR), serum creatinine (Scr), urinary protein quantified at 24 h (Upro), and interleukin-8 (IL-8). Study screening, data collection, as well as quality assessment were performed by two reviewers independently, and analysis was completed using Stata (SE15.0) and Review Manager (5.4). A total number of 13 studies were included in our meta-analysis ( = 1,094 participants). Results showed DGNT combined with conventional western medicine (CWM) was more effective than WM alone in BUA (weighted mean differences (WMD) = -3.49, 95% confidence interval (CI) [-50.36, -32.59], = 0.000), CRP (WMD = -41.48, 95% CI [-4.32, -2.66], = 0.017), ESR (WMD = -6.23, 95% CI [-9.28, -3.17], = 0.019), Scr (WMD = -18.64, 95% CI [-23.09, -14.19], = 0.001), Upro (WMD = -0.72, 95% CI [-0.91, -0.53], = 0.000), and IL-8 (WMD = -4.77, 95% CI [-11.48, 1.94], = 0.000). None of the adverse effects noted were severe, and no life-threatening event was reported. This study shows that DGNT combined with CWM seems to have an effective clinical therapeutic potential. In addition, it also provides a scientific basis for better clinical application of DGNT in the future. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021271607; Identifier: PROSPERO, CRD42021271607.
本研究旨在系统评价当归拈痛汤治疗痛风的有效性和安全性。本研究已在国际前瞻性系统评价注册库（PROSPERO）注册，注册号为CRD42021271607。截至2022年12月，在八个电子数据库中进行了文献研究。本研究的主要结果指标为血尿酸（BUA）和C反应蛋白（CRP）。次要结局指标为红细胞沉降率（ESR）、血清肌酐（Scr）、24小时尿蛋白定量（Upro）和白细胞介素-8（IL-8）。研究筛选、数据收集以及质量评估由两名评价员独立进行，并使用Stata（SE15.0）和RevMan（5.4）完成分析。我们的Meta分析共纳入13项研究（n = 1094名参与者）。结果显示，当归拈痛汤联合西医常规治疗（CWM）在降低BUA（加权均数差值（WMD）=-3.49，95%置信区间（CI）[-50.36，-32.59]，P = 0.000）、CRP（WMD = -41.48，95%CI [-4.32，-2.66]，P = 0.017）、ESR（WMD = -6.23，95%CI [-9.28，-3.17]，P = 0.019）、Scr（WMD = -18.64，95%CI [-23.09，-14.19]，P = 0.001）、Upro（WMD = -0.72，95%CI [-0.91，-0.53]，P = 0.000）和IL-8（WMD = -4.77，95%CI [-11.48，1.94]，P = 0.000）方面比单纯西医治疗更有效。未观察到严重不良反应，也未报告危及生命的事件。本研究表明，当归拈痛汤联合CWM似乎具有有效的临床治疗潜力。此外，它还为当归拈痛汤未来更好地临床应用提供了科学依据。https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021271607；标识符：PROSPERO，CRD42021271607 。
